The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Abstract
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep-wake disturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways passage (commonly of an animal) or illusions were present in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor hallucinations had a higher depression score than non-hallucinators but did not differ in other respects. Logistic regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when minor hallucinations are included, the total prevalence is much higher than previously reported. A simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances, and possibly other factors related to the duration of the disease, act as cofactors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · cited 2×
“DLB are typically recurrent formed visual hallucinations (McKeith et al., 1996).”
Priming and Human Memory Systems
Tulving, E., & Schacter, D. L. (1990) · Science · doi:10.1126/science.2296719 · Cited by 2,595
Complex visual hallucinations. Clinical and neurobiological insights
Manford, M. (1998) · Brain · doi:10.1093/brain/121.10.1819 · Cited by 680
Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference
Foster, N. L., Wilhelmsen, K., Sima, A. A. F., Jones, M. Z., D'Amato, C. J., Gilman, S., & Participants, C. (1997) · Annals of Neurology · doi:10.1002/ana.410410606 · Cited by 634
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease
Krack, P. (1998) · Brain · doi:10.1093/brain/121.3.451 · Cited by 608
Downes, J. J., Roberts, A. C., Sahakian, B. J., Evenden, J. L., Morris, R. G., & Robbins, T. W. (1989) · Neuropsychologia · doi:10.1016/0028-3932(89)90128-0 · Cited by 527 · cited 1×
“Patients with Parkinson’s disease have been 1998), hallucinations were not associated with the dosage of reported to have an impairment in the process of ignoring dopaminergic medication (levodopa or dopaminergic agonirrelevant stimuli (Downes et al., 1989).”
BackgroundRisk factors for nursing home placement in advanced Parkinson's disease
Goetz, C. G., & Stebbins, G. T. (1993) · Neurology · doi:10.1212/wnl.43.11.2227 · Cited by 455
Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome
Teunisse, R. J., Zitman, F. G., Cruysberg, J. R. M., Hoefnagels, W. H. L., & Verbeek, A. L. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90869-7 · Cited by 438
Aarsland, D., Larsen, J. P., Cummings, J. L., & Laake, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.595 · Cited by 348
Cited by
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Non‐motor symptoms in Parkinson’s disease
Poewe, W. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02056.x · Cited by 782
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 685
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., Starkstein, S., Weintraub, D., Poewe, W., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 683
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
Harding, A. J., Broe, G. A., & Halliday, G. M. (2002) · Brain · doi:10.1093/brain/awf033 · Cited by 609
The epidemiology of dementia associated with Parkinson disease
Aarsland, D., & Kurz, M. W. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.034 · Cited by 578
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528
Visual dysfunction in Parkinson’s disease
Weil, R. S., Schrag, A. E., Warren, J. D., Crutch, S. J., Lees, A. J., & Morris, H. R. (2016) · Brain · doi:10.1093/brain/aww175 · Cited by 481
“Mechanistic considerations of minor hallucinations ‘Passage hallucinations’ are illusions of objects, commonly insects and small animals, moving across the peripheries of vision (Fenelon et al., 2000).”
BackgroundInfluentialLevodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease
Harding, A. J., Stimson, E., Henderson, J. M., & Halliday, G. M. (2002) · Brain · doi:10.1093/brain/awf251 · Cited by 443
Collerton, D., Perry, E., & McKeith, I. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000130 · Cited by 437
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
The progression of pathology in longitudinally followed patients with Parkinson’s disease
Halliday, G., Hely, M., Reid, W., & Morris, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0344-8 · Cited by 414
The retina in Parkinson's disease
Archibald, N. K., Clarke, M. P., Mosimann, U. P., & Burn, D. J. (2009) · Brain · doi:10.1093/brain/awp068 · Cited by 408
A 12-Year Population-Based Study of Psychosis in Parkinson Disease
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Goetz, C. G., Stebbins, G. T., Aarsland, D., & Alves, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.166 · Cited by 394
Epidemiology of Parkinson’s disease
Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M., & Larsen, J. P. (2008) · Journal of Neurology · doi:10.1007/s00415-008-5004-3 · Cited by 363
The psychosis spectrum in Parkinson disease
ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.200 · Cited by 355
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Visual hallucinations in Parkinson's disease: a review and phenomenological survey
Barnes, J. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.727 · Cited by 340
The Epidemiology of Dementia Associated with Parkinson's Disease
Aarsland, D., & Kurz, M. W. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00369.x · Cited by 338
Waters, F., Collerton, D., ffytche, D. H., Jardri, R., Pins, D., Dudley, R., Blom, J. D., Mosimann, U. P., Eperjesi, F., Ford, S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu036 · Cited by 325
Epidemiology of psychosis in Parkinson's disease
Fénelon, G., & Alves, G. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.014 · Cited by 330
Hallucinations in Parkinson disease
Diederich, N. J., Fénelon, G., Stebbins, G., & Goetz, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.62 · Cited by 312
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“Among patients with Parkinson's disease, approximately 22% experience complex visual hallucinations (Fenelon et al., 2000).”
BackgroundBurn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310
Williams, D. R., & Lees, A. J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70146-0 · Cited by 300
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Diederich, N. J., Goetz, C. G., & Stebbins, G. T. (2005) · Movement Disorders · doi:10.1002/mds.20308 · Cited by 290
Hallucinations: The science of idiosyncratic perception.
Aleman, A., & Larøi, F. (2008) · American Psychological Association eBooks · doi:10.1037/11751-000 · Cited by 285
Visual and spatial symptoms in Parkinson’s disease
Davidsdottir, S., Cronin-Golomb, A., & Lee, A. (2005) · Vision Research · doi:10.1016/j.visres.2004.11.006 · Cited by 280
Cognitive dysfunction and dementia in Parkinson?s disease
Bosboom, J. L. W., Stoffers, D., & Wolters, E. C. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0168-1 · Cited by 273
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 272
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266
Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K. B., Bloem, B. R., Carod-Artal, F. J., Prakash, R., Esselink, R. A. J., Falup-Pecurariu, C., Gallardo, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c0d416 · Cited by 262
Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E., & Klein, C. (2007) · Movement Disorders · doi:10.1002/mds.21116 · Cited by 259
Cognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase
Pagonabarraga, J., Martinez‐Horta, S., Fernández de Bobadilla, R., Pérez, J., Ribosa‐Nogué, R., Marín, J., Pascual‐Sedano, B., García, C., Gironell, A., & Kulisevsky, J. (2016) · Movement Disorders · doi:10.1002/mds.26432 · Cited by 236
The neural mechanisms of hallucinations: A quantitative meta-analysis of neuroimaging studies
Zmigrod, L., Garrison, J. R., Carr, J., & Simons, J. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.037 · Cited by 226
Psychosis, apathy, depression and anxiety in Parkinson's disease
Gallagher, D. A., & Schrag, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.041 · Cited by 211
Psychiatric aspects of Parkinson?s disease: An Update
Schrag, A. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0483-3 · Cited by 200
“The most consistent risk factor for hallucinations has been found to be cognitive impairment [2, 24, 39], whereas age, duration of disease, disease severity, depression, REM sleep disorder or daytime somnolence, and poor visual acuity have been associated with hallucinations only in some studies [2, 13, 24, 26, 39].”
BackgroundThe serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620060-00004 · Cited by 147
A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease
Papapetropoulos, S., Katzen, H., Schrag, A., Singer, C., Scanlon, B. K., Nation, D., Guevara, A., & Levin, B. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-21 · Cited by 111
Shine, J. M., Muller, A. J., O’Callaghan, C., Hornberger, M., Halliday, G. M., & Lewis, S. J. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.3 · Cited by 106
Lenka, A., Jhunjhunwala, K. R., Saini, J., & Pal, P. K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.005 · Cited by 106
Understanding visual hallucinations: A new synthesis
Collerton, D., Barnes, J., Diederich, N. J., Dudley, R., ffytche, D., Friston, K., Goetz, C. G., Goldman, J. G., Jardri, R., Kulisevsky, J., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105208 · Cited by 83
“They concentrate on cognitive structure (e.g. Collerton et al., 2005) with those structural elements mainly coming from the classic neuropsychological paradigm of functionally specialised modules (e.g. Collerton et al., 2005: F ´ enelon et al., 2000: O ’ Brien et al., 2005).”
BackgroundNeuroimaging in Parkinson’s disease dementia: connecting the dots
Weil, R. S., Hsu, J. K., Darby, R. R., Soussand, L., & Fox, M. D. (2019) · Brain Communications · doi:10.1093/braincomms/fcz006 · Cited by 71
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69
Distress in Parkinson’s disease: contributions of disease factors and metacognitive style
Allott, R., Wells, A., Morrison, A. P., & Walker, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.2.182 · Cited by 55
A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease
Ceravolo, R., Rossi, C., Del Prete, E., & Bonuccelli, U. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1130128 · Cited by 44
Onofrj, M., Thomas, A., & Bonanni, L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1731 · Cited by 41
Thomas, G. E. C., Zeidman, P., Sultana, T., Zarkali, A., Razi, A., & Weil, R. S. (2022) · Brain Communications · doi:10.1093/braincomms/fcac329 · Cited by 38
Zarkali, A., McColgan, P., Leyland, L. A., Lees, A. J., & Weil, R. S. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326630 · Cited by 32
Mohlman, J., Reel, D. H., Chazin, D., Ong, D., Georgescu, B., Tiu, J., & Dobkin, R. D. (2010) · Clinical Case Studies · doi:10.1177/1534650109351305 · Cited by 32
Treatment of behavioural symptoms and dementia in Parkinson's disease
Hanagasi, H. A., & Emre, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00317.x · Cited by 24
Cholinergic deficiency in Parkinson’s disease patients with visual hallucinations
d’Angremont, E., van der Zee, S., Slingerland, S., Slomp, A. C., de Vries, E. F. J., van Laar, T., & Sommer, I. E. (2024) · Brain · doi:10.1093/brain/awae186 · Cited by 22
Stampacchia, S., Bernasconi, F., Van De Ville, D., Amico, E., Pagonabarraga, J., Kulisevsky, J., & Blanke, O. (2025) · doi:10.1101/2025.04.17.649310 · Cited by 5
Metadata
- Authors
- Fenelon, G.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 123
- Issue
- 4
- Pages
- 733-745
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2589302021
- Cited by
- 1,037
- References
- 44
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.